Results: 103

Pérdida de respuesta a terapia anti-TNF en enfermedad inflamatoria intestinal: experiencia en un hospital de referencia en Lima - Perú

RESUMEN Objetivo: Evaluar la respuesta al tratamiento con anti-TNFs en pacientes con enfermedad inflamatoria intestinal. Materiales y métodos: Estudio prospectivo observacional realizado en el Servicio de Gastroenterología del Hospital Nacional Guillermo Almenara, de enero 2015 a agosto 2018. Resu...

Total remission of Tolosa-Hunt Syndrome with single-dose of infliximab

Rev. bras. oftalmol; 79 (1), 2020
Abstract Tolosa-Hunt syndrome is a painful ophthalmoplegia caused by non-specific granulomatous inflammation, corticoid-sensitive, of the cavernous sinus. The etiology is unknown. Recurrences are common. The diagnosis is made by exclusion, and a variety of other diseases involving the orbital apex, super...

Predictive factors for loss of response to anti-tnf in crohns disease

ABCD (São Paulo, Impr.); 33 (2), 2020
ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn's disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn's disease patient...

Latent tuberculosis infection in patients with autoimmune diseases treated with Infliximab and Etanercept

Infectio; 23 (4), 2019
Introduction: Latent tuberculosis infection (LTI) in patients receiving biological therapies is a reality, but this has not been studied in depth in Colombia. Objective: To determine the prevalence of LTI in patients with autoimmune diseases receiving treatment with Infliximab / Etanercept in a referr...

Sarcopenia e gravidade da doença hepática gordurosa não-alcoólica

Arq. gastroenterol; 56 (4), 2019
ABSTRACT BACKGROUND: Non-alcoholic fatty liver disease is characterized by deposition of lipids in the hepatic parenchyma exceeding 5% of liver weight in the absence of other conditions, such as viral or alcoholic hepatitis and metabolic disease. Non-alcoholic fatty liver disease is the most common for...

Atividade física de vida diária, capacidade de exercício e qualidade de vida de pacientes com doença de Crohn em remissão induzida por infliximabe: um estudo preliminar

Arq. gastroenterol; 56 (4), 2019
ABSTRACT BACKGROUND: Physical activity in daily life and exercise capacity have not been assessed in patients with Crohn's disease to date. OBJECTIVE: To evaluate the physical activity in daily life, exercise capacity, quality of life, and prevalence of mood disorders in patients with moderate-to-sev...

Effects of anti-TNF-α in experimental diversion colitis

Acta cir. bras; 34 (10), 2019
Abstract Purpose: To evaluate the effects of infliximab on the inflammation of the colonic mucosa devoid from fecal stream. Methods: Twenty-four rats were submitted to a Hartmann's procedure. They remained for 12 weeks with the fecal derivation to development of diversion colitis on excluded colorectal...

Presentación inusual de psoriasis ostrácea y artritis psoriásica: resultados después de 10 años de manejo con infliximab

Rev. colomb. reumatol; 26 (3), 2019
Resumen La psoriasis es una enfermedad cutánea común, con prevalencia mundial entre el 0,9-8,5%. Es una condición inflamatoria crónica, inmunológicamente mediada, que lleva a hiperplasia epidérmica con gran variedad de formas clínicas. La psoriasis ostrácea es una variante hiperqueratósica infre...

Análise clínica e econômica de “mundo real” da substituição do medicamento Remicade® (infliximabe referência) por Remsima™ (infliximabe biossimilar) em pacientes com artrite reumatoide, espondilite anquilosante e artrite psoriática

Objetivo: O Planserv oferece cobertura à terapia biológica para as patologias de artrite reumatoide (AR), espondilite anquilosante (EA) e artrite psoriática (AP). Em agosto de 2016, 78 pacientes estavam em uso do medicamento Remicade® (infliximabe). Nessa data, o valor do Remicade® foi reduzido para...

Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up

An. bras. dermatol; 94 (4), 2019